Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Risk of admission to hospital for self-harm after admission to hospital for COVID-19: French nationwide longitudinal study.
BJPsych Open
December 2024
Non Communicable Diseases and Trauma Division, Santé publique France, Paris, France; Department of Psychiatry, AP-HP, Louis Mourier Hospital, Paris, France; and INSERM Team 1 - UMR1266, Institute of Psychiatry and Neurosciences, Université de Paris, Paris, France.
Background: Assessing the risk of subsequent self-harm after hospitalisation for COVID-19 is critical for mental health care planning during and after the pandemic.
Aims: This study aims to compare the risk of admission to hospital for self-harm within 12 months following a COVID-19 hospitalisation during the first half of 2020, with the risk following hospitalisations for other reasons.
Method: Using the French administrative healthcare database, logistic regression models were employed to analyse data from patients admitted to hospitals in metropolitan France between January and June 2020.
Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma.
Leuk Lymphoma
February 2025
IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli" and Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
Article Synopsis
- In the absence of direct comparisons, researchers used unanchored matching-adjusted indirect comparisons to evaluate the effectiveness of zanubrutinib against ibrutinib and rituximab in patients with relapsed or refractory marginal zone lymphoma (MZL).
- They applied logistic propensity score models to align patient data from two phase II trials with aggregate data from larger studies involving ibrutinib and rituximab, focusing on factors like previous treatments, MZL subtype, and patient age.
- Results indicated that zanubrutinib provided significant improvements in overall response and progression-free survival compared to both ibrutinib and rituximab for patients with previously treated MZL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!